
ON THE FRONT LINE™
AGAINST INFLUENZA
DAVID ROSS
VP COMMERCIAL OPERATIONS
NORTH AMERICA
Seqirus

1


OUR SEQIRUS PURPOSE
Influenza can kill
We believe it shouldn't be that way
We exist to transform protection against influenza
2 | ON THE FRONT LINE
Seqirus

2


PREPARING FOR A NEW NORMAL
In light of the current COVID-19 crisis, it is imperative that all the key stakeholders work together to ensure more people get immunized against influenza than ever before
We must rally around this effort
3 | ON THE FRONT LINE
Seqirus

3


The seasonal influenza vaccine is the best way to reduce the incidence of influenza[1] and is a vital public health tool in the battle against COVID-19[2]
• Protect against the devastating impact influenza can have
• Minimize the risk of co-infection with COVID-19
• Minimize the burden on the healthcare system
4 | ON THE FRONT LINE
1. https://www.cdc.gov/flu/prevent/vaccinations.htm
2. https://www.washingtonpost.com/health/2020/04/21/coronavirus-secondwave-cdcdirector/
Seqirus

4


COVID-19 has overwhelmed the healthcare system – an anticipated resurgence this fall/winter combined with seasonal influenza will result in an even tougher public health challenge
Our immunization season will be like nothing we've seen before...
Greater importance around flu vaccination
Heightened need for clear guidance and consumer messages
Managing supply and demand throughout the immunization season
Possible disruption to the traditional immunization programs
Uncertain economic conditions may create barrier to immunization
Excessive burden on healthcare systems
Need to adapt for a future with Flu and COVID-19 vaccine
5 | ON THE FRONT LINE
Seqirus

5


Early indicators suggest that healthcare providers and health authorities are planning for an increase in influenza immunization, but with uncertainty on how to best implement their campaigns
Market Trends
• HCPs are planning for increasing demand
• More consumers are expected to seek vaccination
HCP Learnings
• Need for clear immunization objectives and guidelines
• Uncertain about how to adjust for COVID-19 mitigation plans
• Beginning to define creative solutions
Australian Experience
• Increase in patient demand
• Innovative approaches to immunization clinics
6 | ON THE FRONT LINE
Seqirus

6

Need for a shared vision: we must come together as a community to ensure more people get immunized against influenza than ever before

Critical success factors…

- **Clear objectives and guidance** from CDC and other policy bodies
- **Clear messaging and call-to-action** for the public to do their part in this crisis
- **HCPs develop solutions** that consider their patients' and communities' unique needs
- **Vaccine Mfg work closely with customer to manage supply** and ensure doses are where they're needed
- **Utilize the full and EXTENDED** immunization season

7

Seqirus & CSL are working with academia, industry and governments to develop COVID-19 vaccines and therapies

VACCINE ACTIVITIES

- University of Queensland (CEPI) – provision of MF59® adjuvant, recombinant protein expertise from CSL
- MF59 adjuvant provision to preclinical projects

THERAPIES

- Hyperimmune antibodies from convalescent donor plasma
- Hyperimmune antibodies from transgenic cows (human Ig gene)
- Monoclonal antibody collaborations

8

Seqirus has already increased supply by more than 10% to over 55M doses

Age	Description	Presentation
65+ years[1,2]	Egg-based inactivated influenza vaccine with MF59® **adjuvant**	PFS
4+ years[3]	**Cell-based** inactivated quadrivalent influenza vaccine	PFS, MDV
6+ months[4]	Egg-based inactivated quadrivalent influenza vaccine	PFS, MDV

PFS=prefilled syringe. Note: The PFS presentation is preservative free. MDV=multi-dose vial.

1. FLUAD [package insert]. Holly Springs, NC: Seqirus Inc; 2020.
2. FLUAD QUADRIVALENT [package insert]. Holly Springs, NC: Seqirus Inc; 2020.
3. FLUCELVAX QUADRIVALENT [package insert]. Holly Springs, NC: Seqirus Inc; 2020.
4. AFLURIA QUADRIVALENT [package insert]. Holly Springs, NC: Seqirus Inc; 2020.

9

AS YOUR PARTNER IN PUBLIC HEALTH, **THANK YOU** FOR YOUR COMMITMENT AND FOCUS ON THE PREVENTION OF INFLUENZA

10

FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

- If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
- The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.
- Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

ADVERSE REACTIONS

- The most common (≥ 10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

Other adverse events may occur. For a comprehensive list of local and systemic adverse reactions, please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUAD QUADRIVALENT.

11

FLUAD® IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in persons 65 years of age and older.

CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

- If Guillain-Barré syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

ADVERSE REACTIONS

- The most common (≥10%) local (injection site) adverse reactions observed in clinical studies were injection site pain (25%) and tenderness (21%).
- The most common (≥10%) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%), and fatigue (13%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

For more information, please see accompanying US full Prescribing Information for FLUAD.

12

FLUCELVAX® QUADRIVALENT Important Safety Information

INDICATION AND USAGE for FLUCELVAX® QUADRIVALENT (Influenza Vaccine)

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older.

CONTRAINDICATIONS

- Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS

Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

ADVERSE REACTIONS

- The most common (≥10%) local and systemic reactions in adults 18-64 years of age were injection site pain (45.4%), headache (18.7%), fatigue (17.8%), myalgia (15.4%), injection site erythema (13.4%), and induration (11.6%).
- The most common (≥10%) local and systemic reactions in adults ≥65 years of age were injection site pain (21.6%) and injection site erythema (11.9%).
- The most common (≥10%) local and systemic reactions in children 4 to <6 years of age were tenderness at the injection site (46%), injection site erythema (18%), sleepiness (19%), irritability (16%), injection site induration (13%), and change in eating habits (10%).
- The most common (≥10%) local and systemic reactions in children 6 through 8 years of age were pain at the injection site (54%), injection site erythema (22%), injection site induration (16%), headache (14%), fatigue (13%), and myalgia (12%).
- The most common (≥10%) local and systemic reactions in children and adolescents 9 through 17 years of age were pain at the injection site (58%), headache (22%), injection site erythema (19%), fatigue (18%), myalgia (16%), and injection site induration (15%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see accompanying US Full Prescribing Information for FLUCELVAX QUADRIVALENT.

FLUCELVAX QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

13

AFLURIA® QUADRIVALENT (Influenza Vaccine) Important Safety Information

INDICATION

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older.

CONTRAINDICATIONS

- Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

- If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
- Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.

ADVERSE REACTIONS

- In adults 18 through 64 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥40%). The most common systemic adverse events were myalgia and headache (≥20%).
- In adults 65 years of age and older, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥20%). The most common systemic adverse event was myalgia (≥10%).
- In children 5 through 8 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥30%). The most common systemic adverse event was headache (≥40%).
- In children 9 through 17 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥10%).
- In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥ 20%).The most common systemic adverse events were irritability (≥ 30%), diarrhea and loss of appetite (≥ 20%).
- In children 36 through 59 months of age, the most commonly reported injection site reactions were pain (≥ 30%) and redness (≥ 20%). The most commonly reported systemic adverse events were malaise and fatigue, and diarrhea (≥ 10%).

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:

- In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the Pharmajet Stratis Needle-Free Injection System were tenderness (≥80%), swelling, pain, redness (≥60%), itching (≥20%) and bruising (≥10%). The most common systemic adverse events were myalgia, malaise (≥20%), and headache (≥20%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see accompanying full US Prescribing Information for AFLURIA QUADRIVALENT.

AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates.

Pharmajet® and STRATIS® are registered trademarks of Pharmajet.

14